Accordingly, we recommend that the suitable timing to administer TCZ in patients with COVID-19 is in the early stage of the cytokine storm and, in particular, when the baseline level of IL-6 is less than 100 pg/ml. The gene discussed is IL6; the disease is COVID-19.